# Harmony Biosciences Reports Preliminary Q2 WAKIX Revenue of $261M, Reaffirms $1B+ FY26 Guidance

> news · REPORTED · 2026-07-29

Harmony Biosciences reported preliminary Q2 2026 net product revenue of $261M for its narcolepsy drug WAKIX and reaffirmed full-year 2026 net revenue guidance of $1.0B to $1.04B. The company also announced the departure of its CFO.

About Harmony Biosciences Holdings, Inc.: Harmony Biosciences is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for rare neurological diseases, with its flagship product WAKIX (pitolisant) approved for narcolepsy.

- Company: Harmony Biosciences Holdings, Inc.
- Sector: therapeutics
- Primary source: https://ir.harmonybiosciences.com/news-events/news-releases/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.